Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Rabeprazole EC (02310805), PMS-Rabeprazole EC (02310813). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
RABEPRAZOLE SODIUM
All products: general benefit
Other products in the same Health Canada class (A02BC) — coverage varies; not interchangeable
- Pantoprazole (Tecta): general benefit
- Lansoprazole (Prevacid): limited Use 293, 295, 297, 401, 402
- Omeprazole (Losec DR Tab): limited Use 293, 297, 401, 402, Not a benefit
- Pantoprazole (Pantoloc): limited Use 293, 295, 297, 401, 402, Not a benefit
- Dexlansoprazole (Dexilant): not a benefit
- Esomeprazole (Nexium DR Tab): not a benefit
7 more in the class list below
Pariet · DIN 02243796 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pariet · DIN 02243796
Manufacturer: Janssen Inc.; listing date 2002-07-29
Health Canada: Marketed since 2002-04-02 · brand PARIET, ENTERIC-COATED TABLET 10MG · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Janssen inc · schedule Prescription
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734 · Verify on the e-Formulary ↗ (DIN 02243796)
Source record
DIN 02243796: Pariet
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id JAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.6598; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243796
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67734
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: resolved shortage (ended 2024-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243796
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rabeprazole · DIN 02385449 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rabeprazole · DIN 02385449
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-05-29
Health Canada: Marketed since 2012-06-10 · brand RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Rabeprazole: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87107 · Verify on the e-Formulary ↗ (DIN 02385449)
Source record
DIN 02385449: Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385449
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87107
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385449
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rabeprazole EC · DIN 02356511 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rabeprazole EC · DIN 02356511
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2019-05-30 · brand RABEPRAZOLE EC · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Sanis health inc · schedule Prescription
Rabeprazole EC: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84166 · Verify on the e-Formulary ↗ (DIN 02356511)
Source record
DIN 02356511: Rabeprazole EC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356511
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84166
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: resolved shortage (ended 2024-09-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356511
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Rabeprazole · DIN 02314177 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Rabeprazole · DIN 02314177
Manufacturer: Sandoz Canada Inc.; listing date 2008-10-01
Health Canada: Marketed since 2008-07-29 · brand SANDOZ RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Rabeprazole: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79974 · Verify on the e-Formulary ↗ (DIN 02314177)
Source record
DIN 02314177: Sandoz Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id SDZ
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314177
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79974
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: resolved shortage (ended 2024-08-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02314177
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Pariet · DIN 02243797 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pariet · DIN 02243797
Manufacturer: Janssen Inc.; listing date 2007-01-02
Health Canada: Marketed since 2002-04-02 · brand PARIET, ENTERIC-COATED TABLET 20MG · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Janssen inc · schedule Prescription
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67735 · Verify on the e-Formulary ↗ (DIN 02243797)
Source record
DIN 02243797: Pariet
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id JAN
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $3.3197; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243797
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67735
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: resolved shortage (ended 2024-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243797
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rabeprazole · DIN 02385457 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rabeprazole · DIN 02385457
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-05-29
Health Canada: Marketed since 2012-06-10 · brand RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Rabeprazole: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87108 · Verify on the e-Formulary ↗ (DIN 02385457)
Source record
DIN 02385457: Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385457
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87108
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: resolved shortage (ended 2020-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385457
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Rabeprazole EC · DIN 02356538 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Rabeprazole EC · DIN 02356538
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2019-05-30 · brand RABEPRAZOLE EC · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Sanis health inc · schedule Prescription
Rabeprazole EC: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84167 · Verify on the e-Formulary ↗ (DIN 02356538)
Source record
DIN 02356538: Rabeprazole EC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356538
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84167
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: resolved shortage (ended 2024-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356538
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Rabeprazole · DIN 02314185 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Rabeprazole · DIN 02314185
Manufacturer: Sandoz Canada Inc.; listing date 2008-10-01
Health Canada: Marketed since 2008-07-29 · brand SANDOZ RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Rabeprazole: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79975 · Verify on the e-Formulary ↗ (DIN 02314185)
Source record
DIN 02314185: Sandoz Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id SDZ
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02314185
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79975
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: anticipated shortage (last updated 2026-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02314185
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Rabeprazole · DIN 02415283 · 10mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Rabeprazole · DIN 02415283
Manufacturer: Jamp Pharma Corporation; listing date 2023-03-31
Health Canada: Dormant since 2025-07-31 · brand JAMP RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rabeprazole: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89990 · Verify on the e-Formulary ↗ (DIN 02415283)
Source record
DIN 02415283: Jamp Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415283
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89990
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-06-30, last updated 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02415283
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
Jamp Rabeprazole · DIN 02415291 · 20mg · tablet
General benefitDormant since 2025-07-31 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Rabeprazole · DIN 02415291
Manufacturer: Jamp Pharma Corporation; listing date 2023-02-28
Health Canada: Dormant since 2025-07-31 · brand JAMP RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Jamp pharma corporation · schedule Prescription
Jamp Rabeprazole: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89991 · Verify on the e-Formulary ↗ (DIN 02415291)
Source record
DIN 02415291: Jamp Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415291
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89991
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: active shortage (reported 2025-08-07, estimated to end 2026-06-30, last updated 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02415291
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.
Apo-Rabeprazole · DIN 02345579 · 10mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Rabeprazole · DIN 02345579
Manufacturer: Apotex Inc.; listing date 2010-06-14
Health Canada: Cancelled post market since 2025-04-17 · brand APO-RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Apotex inc · schedule Prescription
Apo-Rabeprazole: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83099 · Verify on the e-Formulary ↗ (DIN 02345579)
Source record
DIN 02345579: Apo-Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345579
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83099
Interchangeable products
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: discontinued (2019-09-09, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02345579
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Ran-Rabeprazole · DIN 02298074 · 10mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-25 — choose a marketed DIN from the same-category list.Discontinued 2022-10-25 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-10-25 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Rabeprazole · DIN 02298074
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-01-15
Health Canada: Cancelled post market since 2022-10-25 · brand TARO-RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Sun pharma canada inc · schedule Prescription
Ran-Rabeprazole: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78338 · Verify on the e-Formulary ↗ (DIN 02298074)
Source record
DIN 02298074: Ran-Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298074
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78338
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Teva-Rabeprazole EC · DIN 02296632 · $0.0669
Shortage status: resolved shortage (ended 2023-06-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298074
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-10-25 — choose a marketed DIN from the same-category list.
Teva-Rabeprazole EC · DIN 02296632 · 10mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.Discontinued 2022-01-26 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Rabeprazole EC · DIN 02296632
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Cancelled post market since 2022-01-26 · brand TEVA-RABEPRAZOLE EC · ATC A02BC04 RABEPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients RABEPRAZOLE SODIUM 10 MG · company Teva canada limited · schedule Prescription
Teva-Rabeprazole EC: Formulary list price $0.0669/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.0669 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78199 · Verify on the e-Formulary ↗ (DIN 02296632)
Source record
DIN 02296632: Teva-Rabeprazole EC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000098; group id 696; item number 1719; lccId None; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.0669; ministry $0.0669
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296632
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78199
Interchangeable products
Apo-Rabeprazole · DIN 02345579 · $0.0669
Jamp Rabeprazole · DIN 02415283 · $0.0669
Pariet · DIN 02243796 · $0.0669
Rabeprazole · DIN 02385449 · $0.0669
Rabeprazole EC · DIN 02356511 · $0.0669
Ran-Rabeprazole · DIN 02298074 · $0.0669
Sandoz Rabeprazole · DIN 02314177 · $0.0669
Shortage status: discontinued (2020-03-25, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296632
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Apo-Rabeprazole · DIN 02345587 · 20mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.Discontinued 2025-04-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Rabeprazole · DIN 02345587
Manufacturer: Apotex Inc.; listing date 2010-06-14
Health Canada: Cancelled post market since 2025-04-17 · brand APO-RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Apotex inc · schedule Prescription
Apo-Rabeprazole: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83100 · Verify on the e-Formulary ↗ (DIN 02345587)
Source record
DIN 02345587: Apo-Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02345587
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83100
Interchangeable products
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: discontinued (2018-01-26, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02345587
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-17 — choose a marketed DIN from the same-category list.
Ran-Rabeprazole · DIN 02298082 · 20mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-13 — choose a marketed DIN from the same-category list.Discontinued 2022-09-13 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-13 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-09-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Rabeprazole · DIN 02298082
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-01-15
Health Canada: Cancelled post market since 2022-09-13 · brand TARO-RABEPRAZOLE · ATC A02BC04 RABEPRAZOLE · form Tablet (enteric-coated) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Sun pharma canada inc · schedule Prescription
Ran-Rabeprazole: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78339 · Verify on the e-Formulary ↗ (DIN 02298082)
Source record
DIN 02298082: Ran-Rabeprazole
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id RAN
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02298082
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78339
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Teva-Rabeprazole EC · DIN 02296640 · $0.1338
Shortage status: resolved shortage (ended 2023-06-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02298082
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-09-13 — choose a marketed DIN from the same-category list.
Teva-Rabeprazole EC · DIN 02296640 · 20mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.Discontinued 2022-01-26 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Rabeprazole EC · DIN 02296640
Manufacturer: Teva Canada Limited; listing date 2008-01-15
Health Canada: Cancelled post market since 2022-01-26 · brand TEVA-RABEPRAZOLE EC · ATC A02BC04 RABEPRAZOLE · form Tablet (delayed-release) · route Oral · ingredients RABEPRAZOLE SODIUM 20 MG · company Teva canada limited · schedule Prescription
Teva-Rabeprazole EC: Formulary list price $0.1338/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1338 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78200 · Verify on the e-Formulary ↗ (DIN 02296640)
Source record
DIN 02296640: Teva-Rabeprazole EC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 564000104; group id 696; item number 1720; lccId None; manufacturer id TEV
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1338; ministry $0.1338
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02296640
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78200
Interchangeable products
Apo-Rabeprazole · DIN 02345587 · $0.1338
Jamp Rabeprazole · DIN 02415291 · $0.1338
Pariet · DIN 02243797 · $0.1338
Rabeprazole · DIN 02385457 · $0.1338
Rabeprazole EC · DIN 02356538 · $0.1338
Ran-Rabeprazole · DIN 02298082 · $0.1338
Sandoz Rabeprazole · DIN 02314185 · $0.1338
Shortage status: discontinued (2020-03-25, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296640
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-01-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered
Matched class: 56:40 Miscellaneous G.I. Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, SUCRALFATE
Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL
56:40 Miscellaneous G.I. Drugs
· 6 products · General benefit · strengths: 40mg · Ent Coated Tab
· 16 products ·
Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap
· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2),
Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap
· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10),
Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap
· 22 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 20mg · DR Tab
· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab
· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab
· 2 products · General benefit · strengths: 150mg, 300mg · Cap
· 23 products · Listed, not a benefit (3), General benefit (20) · strengths: 15mg/mL, 150mg, 300mg · Oral Sol, Tab
· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40
and 10 more